EN DE
STOCK COMPARISON

Getein Biotech vs Abbott Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how Getein Biotech (603387) and Abbott Laboratories (ABT) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Getein Biotech as the less overvalued of the two: Getein Biotech trades at ¥9.25 versus a fair value of ¥8.29 (-10%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Getein Biotech
603387.SHG · CNY · Health Care
-10%
upside to fair value
overvalued
Price¥9.25
Fair Value¥8.29
Quality68/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Getein BiotechAbbott Laboratories
Valuation
17.8×P/E (TTM)27.7×
3.86×P/S (TTM)3.89×
1.51×P/B3.36×
12.7×EV/EBITDA15.1×
PEG1.47×
Profitability
22%Net margin14%
28%Operating margin13%
8%Return on equity12%
4%Return on assets6%
Growth
10%Revenue growth (YoY)8%
-16.7%Avg. growth/yr (3Y)0.5%
-1.3%Avg. growth/yr (5Y)5.1%
Balance & size
0.00×Debt / equity0.19×
$616MMarket cap$175B
weakGrowth qualityhealthy

Getein Biotech leads: 8 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Getein Biotechof which business quality 67 · market factors 53 Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
43
50
Quality GrowthAre margins and returns improving?
38
47
CashflowEarnings quality: real cash, not paper profit
81
71
Fin. StrengthBalance sheet, leverage, solvency risk
84
80
InvestmentDisciplined investing over empire-building
70
65
Low VolatilityCalm price path (market factor)
77
83
MomentumPrice trend over the last 3–12 months (market factor)
41
40
52W MomentumDistance to the 52-week high (market factor)
46
33
Net IssuanceBuybacks instead of dilution
83
84

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Getein Biotech

DCF Models¥12.49
Earnings-Based¥6.90
Dividend Discount¥3.32
Multiples¥8.32
Asset-Based¥3.64
Growth DCF¥11.21
Economic Profit¥5.09
Growth Earnings¥10.43

13 of 26 models see the stock below the current price.

Abbott Laboratories

DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Getein Biotech
Bear ¥6.13Fair Value ¥8.29Bull ¥10.44
¥9.25 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Getein Biotech · Health Care

Quality score68 · Top 25%
Fair value upside-10% · above median

Abbott Laboratories · Health Care

Quality score67 · Top 25%
Fair value upside-31% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Getein Biotech as the less overvalued of the two: Getein Biotech trades at ¥9.25 versus a fair value of ¥8.29 (-10%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).

Getein Biotech has the higher quality score (68/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.